xm:左建平
xb:男
zc:研究员
xl:博士
dh:
cz:
dzyj:jpzuo@simm.ac.cn
grzy:
zjlb:研究员；新药；
zw:中科院上海药物研究所研究员、博士生导师、研究组长、药理一室主任
txdz:上海市祖冲之路555号
grjj:中国科学院上海药物研究所二级研究员，所学术委员会副主任，药理一室主任。上海中医药大学兼职教授，大学科技中心免疫生化研究室兼职主任。1983年毕业于上海中医药大学医疗系，1994年于日本大阪大学医学部获得医学博士学位，2000年从美国国立卫生研究院回国进入上海药物研究所工作，从事免疫药理学研究，致力于难治性疾病治疗药物的发现研究。主要针对自身免疫性疾病（类风湿性关节炎、系统性红斑狼疮）和病毒感染性疾病（乙型和丙型病毒肝炎）研发具有自主知识产权的创新药物。先后承担了欧盟国际合作、国家基金委、科技部、中科院、上海市等的多项研究课题，建立了国际水准的免疫抑制和抗病毒药物研发平台，确立了一批原创性候选新药（化学药物1.1类）：雷藤舒（治疗类风关）和异噻氟定（治疗乙肝）已经完成1期临床研究；马来酸蒿乙醚胺（治疗红斑狼疮）已经申报临床研究；另有3个候选新药正在开展全面的临床前研究。回国后相关研究发表SCI论文87篇，获中国、国际专利授权51项。并获国家科技进步二等奖，中国药学科技二等奖，上海市科技进步三等奖，上海药学科技一等奖（2次），全国防治非典型肺炎“优秀科技工作者”，全国归侨侨眷先进个人、和上海市科委“优秀学科带头人”等荣誉和称号。

yjfx:从事免疫药理学研究，致力于难治性自身免疫性疾病和病毒感染性疾病的新药研发，建立了国际水准的免疫抑制和抗病毒药物研发平台，确立了一批原创性候选新药（化学药物1.1类）：雷藤舒（治疗类风湿性关节炎）和异噻氟定（治疗乙型病毒性肝炎）已经完成1期临床研究；马来酸蒿乙醚胺（治疗系统性红斑狼疮）已经申报临床研究；另有3个候选新药正在开展全面的临床前研究。发表SCI研究论文100余篇，获中国、国际专利授权50项。
dblz:(2009.01.01-至今)

1. Xu YB, Yang L, Wang GF, Tong XK, Wang YJ, Yu Y, Jing JF, Feng CL, He PL, Lu W, Tang W, Zuo JP*. Benzimidazole Derivative, BM601, a Novel Inhibitor of Hepatitis B Virus and HBsAg Secretion. Antiviral Res. 2014 Apr 15;107C:6-15

2. Yang L, Shi LP, Chen HJ, Tong XK, Wang GF, Zhang YM, Wang WL, Feng CL, He PL, Zhu FH, Hao YH, Wang BJ, Yang DL, Tang W, Nan FJ, Zuo JP*. Isothiafludine, a novel non-nucleoside compound, inhibits hepatitis B virus replication through blocking pregenomic RNA encapsidation. Acta Pharmacol Sin. 2014 Mar;35(3):410-8

3. He SJ, Lin ZM, Zhang XH, Wu YW, Bai BX, Yang XQ, He PL, Zhu FH, Tang W*, Zuo JP*. Therapeutic effect of a reversible S-adenosyl-L-homocysteine hydrolase inhibitor in lupus-prone NZB×NZW F1 mice via interfering Toll-like receptor engaged antigen-presenting cell responses. Acta Pharmacol Sin. 2014 Feb;35(2):219-29

4. Li X, Li TT, Zhang XH, Hou LF, Yang XQ, Zhu FH, Tang W*, Zuo JP*. Artemisinin Analogue SM934 Ameliorates Murine Experimental Autoimmune Encephalomyelitis through Enhancing the Expansion and Functions of Regulatory T Cell. PLoS One. 2013 Aug 29;8(8):e74108

5. Kong FY, Chen W, He SJ, Lin ZM, Li X, Zhang XH, Yang XQ, Zhu FH, Tong XK, Zhou Y, Tang W, Duan WH*, Zuo JP*. Mycophenolic Acid Derivative 118 Treated Acute Skin Grafting Diseases through Suppressing the IL-17 Production. Acta Pharmacol Sin. 2013 Jul;34(7):921-9

6. Wan CP, Gao LX, Hou LF, Yang XQ, He PL, Yang YF, Tang W, Yue JM*, Li J*, Zuo JP*. Astragaloside triggers T cell activation through regulating the activity of CD45 protein tyrosine phosphatase. Acta Pharmacol Sin. 2013 Apr;34(4):522-30

7. Shi JJ, Ji FH, He PL, Yang YX, Tang W, Zuo JP, Li YC. Synthesis and hepatitis C antiviral activity of 1-aminobenzyl-1H-indazole-3-carboxamide analogues. ChemMedChem. 2013 May;8(5):722-5

8. Lu Y, Chen B, Song JH, Zhen T, Wang BY, Li X, Liu P, Yang X, Zhang QL, Xi XD, Chen SD, Zuo JP, Chen Z, Chen SJ. Eriocalyxin B ameliorates experimental autoimmune encephalomyelitis by suppressing Th1 and Th17 cells. Proc Natl Acad Sci U S A. 2013 Feb 5;110(6):2258-63

9. Du YJ, Lin ZM, Zhao YH, Feng XP, Wang CQ, Wang G, Wang CD, Shi W, Zuo JP, Li F, Wang CZ. Stability of the recombinant anti？erbB2 scFv？Fc？interleukin？2 fusion protein and its inhibition of HER2？overexpressing tumor cells. Int J Oncol. 2013 Feb;42(2):507-16

10. Feng E, Shin WJ, Zhu X, Li J, Ye D, Wang J, Zheng M, Zuo JP, No KT, Liu X, Zhu W, Tang W, Seong BL, Jiang H, Liu H. Structure-Based Design and Synthesis of C-1- and C-4-Modified Analogs of Zanamivir as Neuraminidase Inhibitors. J Med Chem. 2013 Feb 14;56(3):671-84

11. Zhang B, Wang Y, Yang SP, Zhou Y, Wu WB, Tang W, Zuo JP, Li Y, Yue JM. Ivorenolide A, an unprecedented immunosuppressive macrolide from Khaya ivorensis: structural elucidation and bioinspired total synthesis. J Am Chem Soc. 2012 Dec 26;134(51):20605-8

12. Tang W, Zuo JP*. Immunosuppressant discovery from Tripterygium wilfordii Hook f: the novel triptolide analog (5R)-5-hydroxytriptolide (LLDT-8). Acta Pharmacol Sin. 2012 Sep;33(9):1112-8

13. Ye D, Shin WJ, Li N, Tang W, Feng E, Li J, He PL, Zuo JP, Kim H, Nam KY, Zhu W, Seong BL, Tai No K, Jiang H, Liu H. Synthesis of C-4-modified zanamivir analogs as neuraminidase inhibitors and their anti-AIV activities. Eur J Med Chem. 2012 Aug;54:764-70

14. Hou LF, He SJ, Li X, Wan CP, Yang Y, Zhang XH, He PL, Zhou Y, Zhu FH, Yang YF, LiY, Tang W, Zuo JP*. SM934 Treated Lupus-prone NZB × NZW F1 Mice by Enhancing Macrophage Interleukin-10 Production and Suppressing Pathogenic T Cell Development. PLoS ONE. 2012(7)2:e32424. doi:10.1371/journal.pone. **

15. Deng J, Li N, Liu H, Zuo Z, Liew OW, Xu W, Chen G, Tong X, Tang W, Zhu J, Zuo J, Jiang H, Yang CG*, Li J*, Zhu W*. Discovery of Novel Small Molecule Inhibitors of Dengue Viral NS2B-NS3 Protease Using Virtual Screening and Scaffold Hopping. J Med Chem. 2012 Jul 26;55(14):6278-93

16. Liu MM, Zhou L, He PL, Zhang YN, Zhou JY, Shen Q, Chen XW, Zuo JP*, Li W*, Ye DY*. Discovery of flavonoid derivatives as anti-HCV agents via pharmacophore search combining molecular docking strategy. Eur J Med Chem. 2012 Jun;52:33-43

17. Wu J, Zhou Y, Wang LY, Zuo JP, Zhao WM*. Terpenoids from root bark of Celastrus orbiculatus. Phytochemistry 2012 Mar;75:159-68

18. Chao B, Tong XK, Tang W, Li DW, He PL, Jean-Michel Garcia, Zeng LM, Gao AH, Yang L, Li J, Nan FJ, Michael Jacobs, Ralf Altmeyer, Zuo JP*, Hu YH*. Discovery and optimization of 2,4-diaminoquinazoline derivatives as a new class of potent dengue virus inhibitors. J Med Chem. 2012 Apr 12;55(7):3135-43

19. Zhang M, Yang XY, Tang W, Tom W.L.Groeneveld, He PL, Zhu FH, Li J, Lu W, Anna M. Blom, Zuo JP*, Nan FJ*. Discovery and Structural Modification of 1-Phenyl-3-(1-phenylethyl)urea Derivatives as Inhibitors of Complement. ACS Medicinal Chemistry Letters. 2012, 3, 317-321

20. Feng XJ, Yang XY, Luo Y, Li X, Tang W, Zuo JP*, Lu W*. Synthesis and immunomodulating activity of new analogues of fingolimod. Arch Pharm (Weinheim). 2012 Feb;345(2):93-100

21. Wang LY, Chen ZH, Zhou Y, Tang W, Zuo JP, Zhao WM*. Structural revision of periplocosides and periperoxides, natural immunosuppressive agents from the genus Periploca. Phytochemistry. 2011 Dec;72(17):2230-6

22. Xie H, Lin L, Tong L, Jiang Y, Zheng M, Chen Z, Jiang X, Zhang X, Ren X, Qu W, Yang Y, Wan H, Chen Y, Zuo J, Jiang H, Geng M, Ding J*. AST1306, A Novel Irreversible Inhibitor of the Epidermal Growth Factor Receptor 1 and 2, Exhibits Antitumor Activity Both In Vitro and In Vivo. PLoS One. 2011;6(7):e21487

23. Hou LF, He SJ, Li X, Yang Y, He PL, Zhou Y, Zhu FH, Yang YF, Li Y, Tang W, Zuo JP*. Oral administration of Artemisinin analogue SM934 ameliorated the lupus syndromes in MRL/lpr mice by inhibiting Th1 and Th17 cell responses. Arthritis & Rheumatism. 2011 Aug;63(8):2445-55

24. Qu SJ, Wang GF, Duan WH, Yao SY, Zuo JP*, Tan CH*, Zhu DY. Tryptamine derivatives as novel non-nucleosidic inhibitors against hepatitis B virus. Bioorg Med Chem. 2011 May 15;19(10):3120-7

25. Luo Y, Yao JP, Yang L, Feng CL, Tang W, Wang GF, Zuo JP*, Lu W*. Synthesis and anti-hepatitis B virus activity of a novel class of thiazolylbenzimidazole derivatives. Arch Pharm (Weinheim). 2011 Feb;344(2):78-83

26. Wang HB, Zuo JP, Qin GW*. One new sesquiterpene from Saussurea laniceps. Fitoterapia. 2010 Oct;81(7):937-9

27. Luo Y, Yao JP, Yang L, Feng CL, Tang W, Wang GF, Zuo JP*, Lu W. Design and synthesis of novel benzimidazole derivatives as inhibitors of hepatitis B virus. Bioorg Med Chem. 2010 Jul 15;18(14):5048-55

28. Tong XK, Qiu H, Zhang X, Shi LP, Wang GF, Ji FH, Ding HY, Tang W, Ding K*, Zuo JP*. WSS45, a sulfated alpha-D-glucan, strongly interferes with Dengue 2 virus infection in vitro. Acta Pharmacol Sin. 2010 May;31(5):585-92

29. Ni J, Zhu YN, Zhong XG, Ding Y, Hou LF, Tong XK, Tang W, Ono S, Yang YF*, Zuo JP*. The chemokine receptor antagonist, TAK-779, decreased experimental autoimmune encephalomyelitis by reducing inflammatory cell migration into the central nervous system, without affecting T cell function. Br J Pharmacol. 2009 Dec;158(8):2046-56

30. Hou LF, He SJ, Wang JX, Yang Y, Zhu FH, Zhou Y, He PL, Zhang Y, Yang YF, Li Y*, Wei Tang W*, Zuo JP*. SM934, a water-soluble derivative of arteminisin, exerts immunosuppressive functions in vitro and in vivo. Int Immunopharmacol. 2009 Dec;9(13-14):1509-17

31. Wang JX, Hou LF, Yang Y, Tang W, Li Y, Zuo JP*. Inhibition of NO and pro-inflammatory cytokine production by SM905, a novel artemisinin derivative, is associated with suppression of MAPK and NF-κB pathways in RAW 264.7 macrophages. Acta Pharmacol Sin. 2009 Oct;30(10):1428-35

32. Zhang J, Ni J, Chen ZH, Li X, Zhang RJ, Tang W, Zhao WM, Yang YF*, Zuo JP*. Periplocoside A prevents experimental autoimmune encephalomyelitis by suppressing IL-17 production and inhibits differentiation of Th17 cells. Acta Pharmacol Sin. 2009 Aug;30(8):1144-52

33. Wang GF#, Shi LP#, Ren YD#, Liu QF, Liu HF, Zhang RJ, Li Z, Zhu FH, He PL, Tang W, Tao PZ, Li C, Zhao WM, Zuo JP*. Anti-hepatitis B virus activity of chlorogenic acid, quinic acid and caffeic acid in vivo and in vitro. Antiviral Res. 2009 Aug;83(2):186-90

34. Garcia JM, Gao A, He PL, Choi J, Tang W, Bruzzone R, Schwartz O, Naya H, Nan FJ*, Li J*, Altmeyer R, Zuo JP*. High-throughput screening using pseudotyped lentiviral particles: A strategy for the identification of HIV-1 inhibitors in a cell-based assay. Antiviral Res. 2009 Mar;81(3):239-47

35. Zhou R, Tang W, He PL, Yang YF, Li YC, Zuo JP*. (5R)-5-hydroxytriptolide inhibits the immune response of human peripheral blood mononuclear cells. Int Immunopharmacol. 2009 Jan;9(1):63-9

jyjl:1978.09 - 1983.07上海中医药大学（原上海中医学院），医疗系中医专业，医学学士